GlobeNewswire

Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema

Share
  • In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52)1

  • In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase1

  • Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed1

  • Beovu demonstrated an overall well-tolerated safety profile1

  • Novartis intends to submit the data from KESTREL, together with the data from the pivotal Phase III KITE2 study in DME, to health authorities in H1 2021

Basel, December 15, 2020 — Novartis today announced positive findings from the first interpretable results of the Phase III KESTREL study, assessing the efficacy and safety of Beovu® (brolucizumab) 3 mg and 6 mg in diabetic macular edema (DME). Following KITE*, KESTREL is the second pivotal Phase III study of Beovu in DME. The trial met its primary endpoint of non-inferiority in change in best corrected visual acuity (BCVA) from baseline of Beovu 6 mg to aflibercept 2 mg at year one. The trial also met its key secondary endpoint of non-inferiority in average change in BCVA of Beovu 6 mg to aflibercept 2 mg over week 40 through week 521. (Beovu 6 mg is the marketed dose for wet AMD.)

More than half of patients in the Beovu 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase1. Patients treated with Beovu 6 mg experienced significant improvement in change of central subfield thickness (CST) from baseline over the period of week 40 through week 521. As non-inferiority in change in BCVA of brolucizumab 3 mg was not demonstrated in KESTREL, no confirmatory testing of superiority on anatomical outcomes was performed. Further analyses on anatomical outcomes from KESTREL are ongoing.

“These results demonstrate that Beovu has the potential, if approved, to offer DME patients better disease management,” said Dirk Sauer, Global Head Development, Novartis Pharma Ophthalmology. “Based on these data and the strong results we saw earlier this year from the KITE clinical study, we look forward to working with regulatory authorities to bring Beovu to DME patients.”

In KESTREL, Beovu demonstrated an overall well-tolerated safety profile1.

Novartis announced positive topline results from another pivotal phase III study, KITE, in September 2020. The results from KESTREL support the positive results seen in KITE, reinforcing Beovu as a potential new treatment option for DME patients.

The data from KITE and KESTREL will be submitted to upcoming medical meetings and for peer-review publication. Novartis intends to submit the data from both KITE and KESTREL to health authorities in H1 2021 and looks forward to working with regulators worldwide to make Beovu available to DME patients in need.

About Diabetic Macular Edema
Diabetic macular edema (DME) is the leading cause of blindness in young adults in developed countries, including 12% of people with type 1 diabetes and 28% of those with type 2 diabetes3.

Consistently high blood sugar levels associated with diabetes can damage small blood vessels in the eye, causing them to leak fluid4. The resulting accumulation of fluid (known as edema) in the macula can lead to vision loss5. The macula is the area of the retina responsible for sharp, central vision5.

Early symptoms of DME include blurry or wavy central vision and distorted color perception, although the disease can also progress without symptoms at early stages4,5.

About Beovu (brolucizumab)
Beovu (brolucizumab, also known as RTH258) is approved in more than 50 countries, including in the US6, EU7, UK7, Japan8, Canada9 and Australia10, for the treatment of wet AMD. Additional trials are currently ongoing which study the effects of brolucizumab in patients with AMD, diabetic macular edema, retinal vein occlusion and proliferative diabetic retinopathy. Brolucizumab is the most clinically advanced humanized single-chain antibody fragment (scFv)11-13. Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation and drug delivery characteristics13-15.

The proprietary innovative structure results in a small molecule (26 kDa) with potent inhibition of, and high affinity to, all VEGF-A isoforms14. Beovu is engineered to deliver the highest concentration of drug, providing more active binding agents11-13. In preclinical studies, Beovu inhibited activation of VEGF receptors through prevention of the ligand-receptor interaction14-16. Increased signaling through the VEGF pathway is associated with pathologic ocular angiogenesis and retinal edema17. Inhibition of the VEGF pathway has been shown to inhibit the growth of neovascular lesions and suppress endothelial cell proliferation and vascular permeability17.

*Kite Pharma, Inc. is neither a sponsor nor associated with Novartis’ KITE trial.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

References

  1. Novartis data on file. December 2020.
  2. ClinicalTrials.gov. Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KITE). https://clinicaltrials.gov/ct2/show/NCT03481660. Accessed December 2020.
  3. Romero-Aroca P. Managing diabetic macular edema: The leading cause of diabetes blindness. World J Diabetes. 2011;2(6):98-104. doi:10.4239/wjd.v2.i6.98.
  4. National Eye Institute. Diabetic Retinopathy. Available at: https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/diabetic-retinopathy. Accessed December 2020.
  5. National Eye Institute. Macular Edema. Available at: https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/macular-edema#section-id-1556. Accessed December 2020.
  6. Beovu [US prescribing information] East Hanover, NJ. Novartis: 2019
  7. Beovu [summary of product characteristics] Basel, Switzerland. Novartis: 2020.
  8. Pharma Japan. National Health Insurance Pricing. Available at: https://pj.jiho.jp/sites/default/files/pj/document/2020/05/New%20Drugs%20to%20Be%20Added%20to%20NHI%20Price%20List%20on%20May%2020_1.pdf. Accessed December 2020.
  9. Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation. Available at: https://cadth.ca/sites/default/files/cdr/complete/SR0632%20Beovu%20-%20CDEC%20Final%20Recommendation%20%E2%80%93%20May%2025%2C%202020_for%20posting.pdf. Accessed December 2020.
  10. Beovu [prescription medicine decision summary] Australia. Novartis: 2020.
  11. Dugel P, Koh A, Ogura Y, et al; HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72-84
  12. Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: 96-Week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration [published online ahead of print]. Ophthalmology. 2020. https://doi.org/10.1016/j.ophtha.2020.06.028.
  13. Nimz EL, et al. Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primates. The Association for Research in Vision and Ophthalmology (ARVO) annual meeting. 2016. Abstract 4996
  14. Escher D, et al. Single-chain antibody fragments in ophthalmology. Oral presentation at EURETINA congress. 2015. Abstract.
  15. Gaudreault J, et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. ARVO Annual Meeting abstract. Invest Ophthalmol Vis Sci 2012;53:3025. http://iovs.arvojournals.org/article.aspx?articleid=2354604 (link is external). Accessed February 2020
  16. Tietz J, et al. Affinity and Potency of RTH258 (ESBA1008), a Novel Inhibitor of Vascular Endothelial Growth Factor A for the Treatment of Retinal Disorders. IOVS. 2015; 56(7):1501.
  17. Kim R. Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol. 2007;55(6):413-415.

# # #

Novartis Media Relations
E-mail: media.relations@novartis.com

Peter Zuest
Novartis External Communications
+ 41 79 899 9812 (mobile)
peter.zuest@novartis.com



Eric Althoff
Novartis US External Communications
+1 646 438 4335
eric.althoff@novartis.com
Amy Wolf
Novartis Division Communications
+ 41 61 696 58 94 (direct)
+ 41 79 576 07 23 (mobile)
amy.wolf@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

CentralNorth America
Samir Shah+41 61 324 7944Sloan Simpson+1 862 778 5052
Thomas Hungerbuehler        
Isabella Zinck
+41 61 324 8425
+41 61 324 7188

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

FDA Approves Seno Medical’s Ground-Breaking Breast Cancer Diagnostic Technology19.1.2021 16:45:34 CETPress release

Seno’s Imagio® Breast Imaging System helps physicians differentiate between benign and malignant breast lesions using a novel combination of ultrasound and opto-acoustic technology. San Antonio, TX, Jan. 19, 2021 (GLOBE NEWSWIRE) -- The Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA) has granted Texas-based Seno Medical Instruments, Inc. (Seno) premarket approval (PMA) for its groundbreaking diagnostic breast cancer imaging technology that helps physicians better differentiate between benign and malignant breast lesions. The company’s Imagio® Breast Imaging System uses non-invasive opto-acoustic ultrasound (OA/US) technology to provide information on suspicious breast lesions in real time, helping providers characterize and differentiate masses that may - or may not - require more invasive diagnostic evaluation. Breast biopsy procedures caused by false-positive diagnostic assessments in the United States cost the healthcare system more than

USD TENDER OPERATION ANNOUNCEMENT19.1.2021 16:20:00 CETPress release

Bid date, 2021-01-21Bid Date2021-01-21Bid times14.00-14.30 (CET/CEST) on the Bid dateOfferent AmountUSD 10 billionMaximum Permitted Volume of BidsUSD 4 billion from an individual institutionSettlement Date2021-01-25Minimum Permitted Bid Volume100 USD million per bidMaximum Allocation40 per cent of the Offerend amountAllocation timeNot later than 15.00 (CET/CEST) on the Bid dateMaturity Date2021-04-19Maximum Number of Bids10 per individual institutionLowest Interest Supplement0.25 percentage pointsConfirmation of bids to e-maileol@riksbank.se Stockholm, 2021-01-19 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

Rhotex Inc Launches Environmentally-Sound Options to Crypto Mining19.1.2021 16:07:39 CETPress release

TORONTO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rhotex ( www.rhotex.com ) has officially launched 3 miner cases configured with an in-built factory cooling system to ensure 100% efficiency as the chips generate heat. From Rhotex, this first of its kind innovation designed by seasoned crypto industry experts provides an environmentally responsible solution to today's challenges with the traditional miners by consuming lesser power supply compared to the output performance. Rhotex currently offers a range of products in their new offer: RHO Lite, RHO Pro, and RHO Rack, which come with incredible features such as low power consumption, high-performance output, Wi-Fi/ Ethernet connection, easy setup and productive compatibility with various blockchain options. These combined with its inbuilt cooling system increases expected hash rate conversion hence giving it an edge in the industry. All products in the RHO series were painstakingly analyzed and tried under intense conditions. Rhotex Inc.'s a

NetAlly Announces Major Enhancements to AirMapper Ecosystem for More Efficient Workflows in Wi-Fi Deployment and Validation19.1.2021 15:34:01 CETPress release

Multiple enhancements include simultaneous active and passive site surveys, simplified project management in Link-Live cloud service, saving time and enabling collaboration. COLORADO SPRINGS, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- NetAlly announced additional enhancements to its AirMapper™ Wi-Fi site survey ecosystem of products, promising enhancements in customer workflows by simplifying the process of managing survey projects via their complimentary Link-Live™ cloud service. Just last summer, NetAlly announced the AirMapper Ecosystem, comprised of AirMapper Site Survey on the AirCheck® G2 and EtherScope® nXG instruments, with site heatmapping in the Link-Live cloud service, or AirMagnet® Survey PRO software. The handheld instruments allow Wi-Fi network professionals (and even non-experts) to perform a site survey without the need to carry around a laptop, use dongles, or tethered devices, while the cloud service provides a central repository and processing for creating, analyzing,

Payment Technology to Propel Post-COVID Travel Rebound in 202119.1.2021 15:00:00 CETPress release

International Payments Leader Nuvei Partners with Edgar, Dunn & Company to Share Best Practices on Growth Strategies for Travel Operators MONTREAL, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Nuvei (TSX: NVEI and NVEI.U), the payment technology partner of thriving brands, today announced the release of "Redefining travel payments in the post-COVID-19 era," a white paper report and survey pinpointing growth strategies for travel operators in the aftermath of the pandemic, driven by payment technology. Produced in collaboration with Edgar, Dunn & Company (“EDC”), with participation from Visa, this comprehensive study contains data, insights and actionable intelligence for the travel sector as it plans its 2021 comeback, including the critical importance of a digital-first strategy, the most effective and innovative payment models to adopt, and what organizational changes could more swiftly catalyze growth opportunities. The COVID-19 pandemic and its related quarantines and travel restrictions dram

Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)19.1.2021 14:50:00 CETPress release

SAMPO PLC STOCK EXCHANGE RELEASE 19 January 2021 at 3:50 pm Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the total number of Sampo A shares (ISIN: FI009003305) owned directly, indirectly or through financial instruments by BlackRock, Inc. (USA tax ID 32-0174421) and its funds decreased on 18 January 2021 below five (5) per cent of Sampo plc's total stock. Sampo's share capital comprises 555,351,850 shares, of which 554,151,850 are A shares and 1,200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 560,151,850. Total positions of BlackRock, Inc and its funds subject to the notification: % of shares and voting rights (total of A)% of shares and voting rights through financial instruments (total of B)Total of both in % (A+B)Re

Vertex Extends Relationship with Adobe as a Premier Partner in the Adobe Exchange Program19.1.2021 14:37:00 CETPress release

Partnership and integrated tax software simplify tax compliance, creating seamless customer experience for customers KING OF PRUSSIA, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a leading provider of tax technology and services, announced that it is extending its relationship with Adobe as a Premier Partner in the Adobe Exchange Program. Vertex will continue to provide seamlessly integrated tax calculation functionality for Magento Commerce, part of Adobe Experience Cloud. Vertex delivers a tax technology automation solution to Magento Commerce merchants that need to collect sales tax, as well as file and pay returns. The constant changes in rules and rates across jurisdictions, states, and products create a need for automated software to accurately calculate tax throughout the complete purchase lifecycle. Vertex is among a select number of partner technologies bundled into core Magento Commerce code in order to simplify the onboarding